Bachelor of Science

German American Bank Announces Scott Powell as Chief Credit Officer

Retrieved on:

Monday, March 4, 2024

Acquisition, German Americans, First Security Bank, Bachelor of Science, Security Bank, Culture, First, Retirement, MBA, McKendree University, University, Management

JASPER, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- German American Bancorp, Inc. (Nasdaq: GABC) and its banking subsidiary, German American Bank, announces that Scott Powell has been appointed Executive Vice President, Chief Credit Officer, effective April 1, 2024.

Key Points:

JASPER, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- German American Bancorp, Inc. (Nasdaq: GABC) and its banking subsidiary, German American Bank, announces that Scott Powell has been appointed Executive Vice President, Chief Credit Officer, effective April 1, 2024.
Powell will succeed current Executive Vice President and Chief Credit Officer, Keith A. Leinenbach, who will be retiring.
As an executive, he has been instrumental in growing our company both organically and through acquisitions, and driving superior financial performance.”
Powell joined German American Bank through the acquisition of First Security Bank in 2018 where he served as an executive and Chief Credit officer.
He currently serves in the role of Regional Credit Officer at German American.

Sitryx Therapeutics makes key appointments to strengthen business operations and progress immunometabolism-targeting pipeline into clinical development

Retrieved on:

Monday, March 4, 2024

At Sitryx, Ben joins the Company’s senior leadership team and will oversee the Company’s day-to-day operations and finance.

Key Points:

At Sitryx, Ben joins the Company’s senior leadership team and will oversee the Company’s day-to-day operations and finance.
Before becoming Head of Clinical Operations at Sitryx, Gordon was Vice President of Development Operations at biotech company Mission Therapeutics, where he oversaw the design and execution of the company’s clinical development assets.
Leading Sitryx’s clinical operations, Gordon will work with the development team as it progresses its assets beyond pre-clinical research and into clinical-stage drug development.
Dr Ravi Rao, Chief Medical Officer of Sitryx, commented: “Sitryx has made excellent progress with its pipeline of potential first- and best-in-class, disease-modifying therapeutics.

Gevo Hires Damien Perriman as Chief Business Development Officer

Retrieved on:

Monday, February 26, 2024

University, Bachelor of Science, Genomatica, GEVO, MBA, Anderson School of Management, Policy, UCLA, Dow Chemical Company, Management

ENGLEWOOD, Colo., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) is pleased to announce that Damien Perriman has been hired as Chief Business Development Officer to lead the effort to bring in new business in a wider variety of industry sectors and expand the brand footprint for the company.

Key Points:

ENGLEWOOD, Colo., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) is pleased to announce that Damien Perriman has been hired as Chief Business Development Officer to lead the effort to bring in new business in a wider variety of industry sectors and expand the brand footprint for the company.
Damien is a highly experienced business executive with proven thought leadership and a track record for establishing partnerships with companies looking to engage with disruptive bio-based technologies.
He held business development lead roles at Verdezyne and contributed to bioscience ventures at Dow Chemical.
"Gevo is in an exciting growth phase, with partners primed to embrace widespread utilization of sustainable resources, be it for fuel or chemicals," Perriman noted.

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Retrieved on:

Tuesday, February 20, 2024

This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.

Key Points:

This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.
“We are thrilled to have Masad and Jim lend their decades of experience in oligonucleotide research and development to our Strategic Advisory Board,” said Stefan Lutz, PhD, Senior Vice President of Research at Codexis.
Dr. Damha is a co-founder of Anagenis, Inc., a start-up with proprietary antisense technologies (ANA and FANA).
Presently, Dr. Lalonde serves as Chairman of the Board of Directors at Willow Biosciences and as a Scientific Advisory Board member at Bota Biosciences, bitBiome, Curie Co. and Invizyne.

RetinAI Discovery® platform and AI tools launched to improve decision workflows, referrals and patient management in Clinics for Ophthalmologists and Optometrists

Retrieved on:

Tuesday, February 20, 2024

US (“RetinAI”), a leader in developing software solutions for image processing and artificial intelligence (AI) in Ophthalmology, has launched RetinAI Discovery® for Clinics ('Discovery'), with two product versions to address the needs of Ophthalmologists and Optometrists.

Key Points:

US (“RetinAI”), a leader in developing software solutions for image processing and artificial intelligence (AI) in Ophthalmology, has launched RetinAI Discovery® for Clinics ('Discovery'), with two product versions to address the needs of Ophthalmologists and Optometrists.
Discovery for Clinics and its expert-level AI models have been designed to accelerate and enhance clinical decision workflows, teleophthalmology management, referral decisions and patient management generating data efficiencies and enhancing decisions for clinics.
The vendor neutral and multi-modality platform harmonizes, aggregates, and connects large datasets on a single, cloud-based repository for data.
The data is then automatically analyzed with RetinAI’s CE-marked and Research Use Only (RUO) AI algorithms for accelerated and AI-biomarker based treatment decisions.

Raji Manasseh Joins Aristotle Capital Management as a Managing Director, Client Portfolio Manager

Retrieved on:

Thursday, March 7, 2024

Asset Management, Professional Services, Finance, Senior, Multimedia, PIMCO, Bachelor of Science, Goldman Sachs, CFA, FINRA, Wheaton College, Head, Security (finance)

Aristotle Capital Management, LLC (“Aristotle”) today announced an addition to its investment team by appointing Raji Manasseh, CFA, as a Managing Director, Client Portfolio Manager.

Key Points:

Aristotle Capital Management, LLC (“Aristotle”) today announced an addition to its investment team by appointing Raji Manasseh, CFA, as a Managing Director, Client Portfolio Manager.
Mr. Manasseh will serve as a primary liaison between the Aristotle Capital Management investment team and its clients and prospects.
View the full release here: https://www.businesswire.com/news/home/20240307611643/en/
Raji Manasseh, Managing Director, Client Portfolio Manager at Aristotle Capital Management (Photo: Business Wire)
“We are thrilled to welcome Raji to Aristotle,” said Ms. Llinás.
Prior to joining PIMCO, he served as Client Portfolio Manager at Goldman Sachs Asset Management (GSAM) for fundamental U.S. growth equity.

VedaBio Strengthens Management Team

Retrieved on:

Wednesday, March 6, 2024

Biotechnology, Health Technology, Health, Other Health, Bachelor of Science, Doctor of Philosophy, Growth, University, Sherlock Biosciences, Quest Diagnostics, Executive, Thermo Fisher Scientific, Management

He previously held the role of Executive Chairman, President and Chief Operating Officer at VedaBio.

Key Points:

He previously held the role of Executive Chairman, President and Chief Operating Officer at VedaBio.
“It is a privilege to serve a team that is truly operating at the forefront of scientific innovation, as we work together to create a fundamental new model in the field of molecular detection,” said Fred Sweeney, PhD, President and Chief Executive Officer, VedaBio.
“I am continuously impressed by the executive and scientific talent of the VedaBio team.
The VedaBio team shares a deep commitment to the mission of revolutionizing molecular detection and to empowering major advances across multiple applications,” said Craig Asher, Lead Director of VedaBio and Managing Director, OMX Ventures.

Laura Hay Named to MetLife’s Board of Directors

Retrieved on:

Wednesday, February 28, 2024

MetLife, Inc. (NYSE: MET) today announced that Laura Hay has been elected to its board of directors, effective immediately.

Key Points:

MetLife, Inc. (NYSE: MET) today announced that Laura Hay has been elected to its board of directors, effective immediately.
View the full release here: https://www.businesswire.com/news/home/20240227857191/en/
LAURA HAY NAMED TO METLIFE’S BOARD OF DIRECTORS (Photo: Business Wire)
Hay was Global Head of Insurance at KPMG LLP prior to her retirement in 2023, where she was an advisor on transformation, growth strategy, customer-focused innovation and risk mitigation to global boards and executive management teams.
Hay was a member of the KPMG Global Financial Services Leadership Team and served on KPMG’s U.S. board of directors for five years and the KPMG Americas board for three years.
Hay was named an “Inspiring Woman in Finance” in 2022 by the CPCU Society.

Seek Labs Welcomes Alison O’Mahony, PhD as new Vice President of Pharmaceutical Research

Retrieved on:

Thursday, February 22, 2024

Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel gene therapies, announced today the appointment of Alison O’Mahony, PhD as Vice President of Pharmaceutical Development.

Key Points:

Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel gene therapies, announced today the appointment of Alison O’Mahony, PhD as Vice President of Pharmaceutical Development.
With nearly 20 years of experience in R&D, phenotypic drug discovery, and assay and scientific operations, O’Mahony brings extensive knowledge and expertise to Seek Labs where she will spearhead the pharmaceutical research division, leading strategic initiatives to advance Seek Labs’ innovation in novel gene therapies.
"We are delighted to welcome Alison O’Mahony to Seek Labs as our new Vice President of Pharmaceutical Development," said Jared Bauer, CEO.
She also serves on professional boards including Talent Ready Utah, Breakthrough Cancer Research, and the Inflammation Research Association.

D2L Expands Leadership Team

Retrieved on:

Wednesday, March 6, 2024

Senior, Western University, Customer success, SVP, Record, Athabasca University, Bachelor of Science, BlackBerry, Manulife, MBA, Culture, Collier, University, Management

"We are thrilled to welcome Amy and Lee to the D2L executive leadership team," said John Baker, CEO and Founder of D2L.

Key Points:

"We are thrilled to welcome Amy and Lee to the D2L executive leadership team," said John Baker, CEO and Founder of D2L.
Amy's appointment is a strong addition to our team, and we look forward to her work in building a company culture in which talent thrives.
With over a decade at D2L, most recently as Senior Vice President, Sales & Customer Success, Lee brings a wealth of experience from within the organization.
Lee's accomplishments at D2L, coupled with his background in sales at BlackBerry, help equip him to drive revenue growth and go-to-market excellence globally.